Latest Ratios: P/E Ratio -0.8x · EV/EBITDA N/A · ROE -738.8%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $8M | $35M | $308M | — | — | — | — | — |
| Enterprise Value | $9M | $37M | $304M | — | — | — | — | — |
| P/E Ratio → | -0.84 | — | — | — | — | — | — | — |
| P/S Ratio | 349.56 | 1620.53 | — | — | — | — | — | — |
| P/B Ratio | — | — | 73.82 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1690.73 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.6% | 80.6% | — | — | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | -40873.2% | -40873.2% | — | — | -1471.4% | -612.4% | -164.4% | — |
| Net Profit Margin | -39662.8% | -39662.8% | — | — | -2125.2% | -686.4% | -146.9% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -738.8% | -738.8% | -58.5% | — | — | — | — | — |
| ROA | -146.9% | -146.9% | -76.8% | -2488.0% | -1097.6% | -719.5% | -595.0% | -49323.6% |
| ROIC | -4197.2% | -4197.2% | — | — | — | — | — | — |
| ROCE | -754.5% | -754.5% | -73.7% | — | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.05 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.85 | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -129.94 | -129.94 | -8.82 | -20.87 | -5.69 | -35.85 | -121.25 | -8.61 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.65 | 0.65 | 2.31 | 0.00 | 0.01 | 0.08 | 0.13 | 0.00 |
| Quick Ratio | 0.63 | 0.63 | 2.31 | 0.00 | 0.01 | 0.08 | 0.13 | 0.00 |
| Cash Ratio | 0.51 | 0.51 | 1.88 | 0.00 | 0.01 | 0.06 | 0.05 | 0.00 |
| Asset Turnover | — | 0.00 | — | — | 0.99 | 0.96 | 2.05 | — |
| Inventory Turnover | 0.03 | 0.03 | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | 40.91 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $35M | $29M | $33M | $33M | $9M | $9M | $9M |
Imminent liquidity and dilution
As reported in recent financial filings, JUNS trades at a P/S ratio of 466.08, a figure that appears to reflect extreme market skepticism regarding the company's ability to successfully commercialize its proprietary delivery platform rather than any fundamental earnings-based valuation metric typical of established healthcare firms.
The elevated P/S multiple is largely a mathematical artifact of the company's negligible revenue base rather than a signal of premium growth expectations. Investors should monitor whether this valuation compresses further as the company likely pursues dilutive equity financing to sustain its clinical pipeline.
Based on the company's reported figures, the ROIC has deteriorated to -15.6% as of 2025Q2, illustrating a persistent inability to generate productive returns on invested capital while the firm remains in a pre-revenue, high-expenditure clinical development phase that consumes shareholder equity at an accelerating rate.
The negative return profile suggests that the capital allocated to R&D and clinical trials is not yet creating tangible value, which is common for early-stage biotech but warrants caution. The trend indicates that until a clinical milestone is reached, capital efficiency will likely remain deeply negative.
According to quarterly data, the current ratio has compressed to 0.51 in 2026Q1, down from 2.31 in 2024Q4, indicating that the company's ability to cover short-term liabilities with liquid assets is severely compromised and warrants immediate concern regarding the firm's ongoing viability as a going concern.
This rapid contraction in liquidity suggests that the company is exhausting its cash reserves faster than it can secure alternative funding. The current ratio below 1.0 implies that current liabilities now exceed current assets, leaving the firm highly vulnerable to operational disruptions or unexpected regulatory delays.
While the reported gross margin of 76.6% in 2026Q1 might appear strong, it is a misleading metric for JUNS, as it obscures the fact that the company is not yet a commercial entity and lacks the scale to cover its massive R&D-driven operating losses.
Analysts should prioritize the operating margin and cash burn rate over gross margin, as the latter is distorted by the lack of meaningful product sales. Relying on gross margin in this context may lead to an incorrect assumption of operational profitability that does not exist.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying JUNS stock.
Jupiter Neurosciences, Inc.'s current P/E ratio is -0.8x. This places it at the 50th percentile of its historical range.
Jupiter Neurosciences, Inc.'s return on equity (ROE) is -738.8%. The historical average is -58.5%.
Based on historical data, Jupiter Neurosciences, Inc. is trading at a P/E of -0.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Jupiter Neurosciences, Inc. has 80.6% gross margin and -40873.2% operating margin.